Drug Profile
GSK 2816126
Alternative Names: GSK-2816126Latest Information Update: 28 Mar 2023
Price :
$50
*
At a glance
- Originator GlaxoSmithKline
- Developer GlaxoSmithKline; GSK
- Class Antineoplastics
- Mechanism of Action Enhancer of zeste homolog 2 protein inhibitors; Histone modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Diffuse large B cell lymphoma; Follicular lymphoma
- Discontinued Acute myeloid leukaemia
Most Recent Events
- 28 Mar 2023 Discontinued - Preclinical for Acute myeloid leukaemia in United Kingdom (IV)
- 28 Mar 2020 No recent reports of development identified for phase-I development in Diffuse large B cell lymphoma(Second-line therapy or greater) in France (IV, Infusion)
- 28 Mar 2020 No recent reports of development identified for phase-I development in Follicular lymphoma(Second-line therapy or greater) in France (IV, Infusion)